Table 1 Characteristics of patients receiving rifaximin for small intestine bacterial overgrowth
From: Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
N (%) | |
|---|---|
Total | 19 (100) |
Male | 7(36.8) |
Age, years (SD) | 56.5 (17.6) |
Medications | |
Anticholinergics | 5 (26.3) |
Calcium channel blocker | 3 (15.8) |
Proton pump inhibitor | 12 (63.2) |
Comorbidities | |
Diabetes mellitus | 5 (26.3) |
Sjogren’s syndrome | 1 (12.5) |
Penicillin allergy | 3 (15.8) |